Photo of Guru P. Sonpavde adventhealthcancerinstitute.com
Nov 14, 2023, 03:56
Guru P. Sonpavde: Honored to write this commentary…
Guru P. Sonpavde, GU Oncology Director at Advent Health Cancer Institute, shared on X/Twitter:
“Nivolumab Plus Gemcitabine–Cisplatin as first-line therapy for Advanced Urothelial Carcinoma bladder cancer – honored to write this commentary – what is the role of Gem-Cis-Nivo in the context of EV-pembro and the platinum combination followed by maintenance Avelumab paradigms?”
For the article click here.
Source: Guru P. Sonpavde/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56